CLINICAL_TRIALS
trial_result
· 2018-10-17
Clinical Trial Update: A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma [Phase 3]
Summary
Phase 3 trial of vemurafenib as adjuvant therapy in surgically resected BRAF-mutant melanoma completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2018-10-17